ライフサイエンスコーパス: extracorporeal

1 mps and connecting tubes, to build a routine extracorporeal blood circuit but a minimal dialysate cir

2 High extracorporeal blood flow venovenous extracorporeal memb

3 particularly in whom cross-clamping without extracorporeal bypass can be omitted.

4 Mechanical adjuncts such as extracorporeal carbon dioxide removal may be useful to n

5 d streptokinase 1 million units, and control extracorporeal cardiopulmonary resuscitation (c-ECPR), w

6 Although extracorporeal cardiopulmonary resuscitation (E-CPR) can

7 re allocated into two experimental groups: t-extracorporeal cardiopulmonary resuscitation (t-ECPR) gr

8 s associated with increased mortality during extracorporeal cardiopulmonary resuscitation compared wi

9 ular fibrillation cardiac arrest followed by extracorporeal cardiopulmonary resuscitation for 6 hours

10 The addition of thrombolytic to extracorporeal cardiopulmonary resuscitation significant

11 of spontaneous heart beat, weanability from extracorporeal cardiopulmonary resuscitation, and left v

12 rane oxygenation for respiratory failure and extracorporeal cardiopulmonary resuscitation.

13 real membrane oxygenation, and 412 underwent extracorporeal cardiopulmonary resuscitation.

14 ne oxygenation for cardiogenic shock, and 3) extracorporeal cardiopulmonary resuscitation.

15 brillation was attempted after 30 minutes of extracorporeal cardiopulmonary resuscitation.

16 When the device is integrated into an extracorporeal circuit in pig endotoxemia or heparin the

17 L at 1 and 3 hours, respectively, within the extracorporeal circuit.

18 -hour hemodialysis session, during which the extracorporeal circulation blood flow was maintained bet

19 10) or an oscillation group (anesthesia and extracorporeal circulation for 20 hr with artificial PaO

20 andomized to a control group (anesthesia and extracorporeal circulation for 20 hr with constant PaO2,

21 High microbubble volume in the extracorporeal circulation loop and a high number of mic

22 thrombosis, to inhibit contact activation in extracorporeal circulation, and to treat the swelling di

23 Extracorporeal circulatory support is a life-saving tech

24 e coronary syndrome diagnosis and treatment, extracorporeal circulatory support setting, outcome defi

25 cute coronary syndrome patients treated with extracorporeal circulatory support was performed.

26 The event rates of extracorporeal circulatory support-related complications

27 Secondary outcomes were extracorporeal circulatory support-related complications

28 cute coronary syndrome patients treated with extracorporeal circulatory support.

29 cute coronary syndrome patients treated with extracorporeal circulatory support.

30 udies are needed to optimize and standardize extracorporeal circulatory support.

31 ion medicine paradigm to the emerging use of extracorporeal CO2 removal (ECCO2R) for ultraprotective

32 Alternatively, lower-flow extracorporeal CO2 removal devices may be used to reduce

33 New therapies, including a novel low-flow extracorporeal CO2 removal technique and mesenchymal ste

34 ented rhythm, location of event in hospital, extracorporeal CPR, and hypotension as the cause of arre

35 Therefore, the extracorporeal delivery approach of therapeutic enzymes

36 Accordingly, a novel, generally-applicable extracorporeal delivery of a therapeutic enzyme is propo

37 nd hyperuricemic geese, a native uricase via extracorporeal delivery was active in the dialysate for

38 ntial for the management of patients who use extracorporeal devices, receive anticoagulation therapy

39 l of PBUTs can be significantly increased by extracorporeal infusion of PBUT binding competitors.

40 racranial hemorrhage is a consequence of the extracorporeal intervention or of the underlying severe

41 cardiac catheterization laboratory (CCL) for extracorporeal life support (ECLS) and revascularization

42 Extracorporeal life support can lead to rapid reversal o

43 , adjusting for demographics, diagnosis, pre-extracorporeal life support care, extracorporeal life su

44 The extracorporeal life support cohorts were as follows: 1)

45 ), and mortality were evaluated across three extracorporeal life support cohorts.

46 Support International Registry who received extracorporeal life support for cardiac support between

47 mortality in pediatric patients who receive extracorporeal life support for cardiac support.

48 atabase of patients temporary implanted with extracorporeal life support for refractory arrhythmic st

49 ccurred after a median time of 3 hours after extracorporeal life support implantation for the remaini

50 Patients' characteristics and outcomes after extracorporeal life support implantation were analyzed.

51 all North American pediatric patients in the Extracorporeal Life Support International Registry who r

52 Extracorporeal life support is used for patients with se

53 We examined data from the Extracorporeal Life Support Organisation registry to ide

54 Data reported to Extracorporeal Life Support Organization from 350 intern

55 re from 1989 to 2013 were extracted from the Extracorporeal Life Support Organization international m

56 Extracorporeal Life Support Organization Registry databa

57 ormed a retrospective cohort study using the Extracorporeal Life Support Organization Registry.

58 eal membrane oxygenation and included in the Extracorporeal Life Support Organization registry.

59 Retrospective analysis of the Extracorporeal Life Support Organization's data registry

60 run for respiratory failure reported to the Extracorporeal Life Support Organization's data registry

61 rane oxygenation centers registered with the Extracorporeal Life Support Organization.

62 thresholds and mortality in three cohorts of extracorporeal life support patients.

63 Extracorporeal life support seems an efficient therapy f

64 imed at analyzing the efficacy and safety of extracorporeal life support to treat refractory arrhythm

65 oningen in the period 2010-2013 and received extracorporeal life support treatment.

66 nosis, pre-extracorporeal life support care, extracorporeal life support variables, and extracorporea

67 The remaining 13 patients (50%) had extracorporeal life support withdrawn after 6.7 +/- 3.6

68 oxygenation therapy with prone ventilation, extracorporeal life support, high-frequency oscillatory

69 Of 7,106 patients undergoing cardiac extracorporeal life support, the majority of patients we

70 s (50%) eventually died, none of them due to extracorporeal life support-related complications, but m

71 , extracorporeal life support variables, and extracorporeal life support-related complications.

72 return of spontaneous circulation and 22% by extracorporeal life support.

73 timal medical therapy were implanted with an extracorporeal life support.

74 sets of cardiac surgery patients who require extracorporeal life support.

75 th mortality in children who require cardiac extracorporeal life support.

76 te hospital admission in which they received extracorporeal life support.

77 Due to the limited number of donor organs, extracorporeal liver support is suggested as an appealin

78 Under these circumstances, extracorporeal lung support (ECLS) may be beneficial in

79 0.01), intubation (58% vs. 8.3%; p < 0.01), extracorporeal membrane oxygenation (17.9% vs. 1.7%, p <

80 ac disease duration greater than 2 years pre-extracorporeal membrane oxygenation (2.8 [1.2-6.9]), and

81 between patients managed with versus without extracorporeal membrane oxygenation (22% vs 30%) (p = 0.

82 0.5] vs. 16.5 [9-25.5] days; p < 0.001), and extracorporeal membrane oxygenation (25.5 [10.75-54] vs.

83 core II 37 [32-47]) who underwent peripheral extracorporeal membrane oxygenation (87% veno-venous) fo

84 d function between recipients from donors on extracorporeal membrane oxygenation (92.7% [85.9-96.3%])

85 and matching recipients from donors without extracorporeal membrane oxygenation (95.4% [93.0-97.0%])

86 Extracorporeal membrane oxygenation (ECMO) has long serv

87 Extracorporeal membrane oxygenation (ECMO) is being incr

88 Utilization of extracorporeal membrane oxygenation (ECMO) is expanding

89 RATIONALE: Extracorporeal membrane oxygenation (ECMO) is used for r

90 High extracorporeal blood flow venovenous extracorporeal membrane oxygenation (ECMO) may therefore

91 Extracorporeal membrane oxygenation (ECMO) provides circ

92 eoperative inotropic (OR, 2.61; P=0.001) and extracorporeal membrane oxygenation (OR, 1.68; P=0.05) s

93 Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increas

94 73.0%; p < 0.001), oxygen rescue therapies (extracorporeal membrane oxygenation 5.8% vs 0.9%; p = 0.

95 of thrombocytopenia in patients supported by extracorporeal membrane oxygenation after cardiac surger

96 Among these patients, 64 donors on extracorporeal membrane oxygenation and 10,805 donors wi

97 Extracorporeal membrane oxygenation and adrenalectomy sh

98 deficits in school-age survivors of neonatal extracorporeal membrane oxygenation and congenital diaph

99 ere acute lung failure receiving veno-venous extracorporeal membrane oxygenation and explore risk fac

100 ssociations between survival and various pre-extracorporeal membrane oxygenation and extracorporeal m

101 Univariate analysis identified pre-extracorporeal membrane oxygenation and extracorporeal m

102 2 adult patients supported with venoarterial extracorporeal membrane oxygenation and included in the

103 n in spite of treatment with venous-arterial extracorporeal membrane oxygenation and mechanical circu

104 scribe donors after brain death with ongoing extracorporeal membrane oxygenation and to analyze the o

105 t school-age (8-12 yr) survivors of neonatal extracorporeal membrane oxygenation and/or congenital di

106 Adolescents treated with neonatal extracorporeal membrane oxygenation are at risk of verba

107 Major complications caused by extracorporeal membrane oxygenation are bleeding, thromb

108 cquired pneumonia in adults receiving rescue extracorporeal membrane oxygenation are mainly confined

109 Brain-dead patients with ongoing extracorporeal membrane oxygenation are suitable for org

110 embrane oxygenation (2.8 [1.2-6.9]), and pre-extracorporeal membrane oxygenation blood lactate greate

111 ed blood stream infections, two colitis, one extracorporeal membrane oxygenation cannula infection, a

112 Pre-extracorporeal membrane oxygenation cardiac arrest, cont

113 In a multivariable model, age, pre-extracorporeal membrane oxygenation cardiac arrest, the

114 Support Organization from 350 international extracorporeal membrane oxygenation centers during 1992-

115 Three-hundred ninety-four extracorporeal membrane oxygenation centers registered w

116 , increased by 36% and 58%, respectively, by extracorporeal membrane oxygenation day 3.

117 State Behavioral Scale scores -3/-2 (34%) by extracorporeal membrane oxygenation day 3.

118 ted blood flow from peripheral veno-arterial extracorporeal membrane oxygenation due to intra-aortic

119 ear, participants returned for two simulated extracorporeal membrane oxygenation emergencies (Sim2-pu

120 Participants had a preintervention simulated extracorporeal membrane oxygenation emergency (Sim1-reci

121 e regression analysis identified certain pre-extracorporeal membrane oxygenation factors as predictor

122 e logistic regression to explore patient and extracorporeal membrane oxygenation factors associated w

123 pre-extracorporeal membrane oxygenation and extracorporeal membrane oxygenation factors.

124 tcomes of patients treated with venoarterial-extracorporeal membrane oxygenation for acute decompensa

125 ed five patients implanted with venoarterial-extracorporeal membrane oxygenation for acute decompensa

126 05 patients were implanted with venoarterial-extracorporeal membrane oxygenation for acute decompensa

127 of 105 patients implanted with venoarterial-extracorporeal membrane oxygenation for acute decompensa

128 lantation recipients treated with venovenous extracorporeal membrane oxygenation for acute respirator

129 ll transplantation do not support the use of extracorporeal membrane oxygenation for acute respirator

130 sedation management in children supported on extracorporeal membrane oxygenation for acute respirator

131 on for respiratory failure, 2) veno-arterial extracorporeal membrane oxygenation for cardiogenic shoc

132 d data on adult patients (> 18 yr) receiving extracorporeal membrane oxygenation for community-acquir

133 uded 4,988 adults supported with veno-venous extracorporeal membrane oxygenation for respiratory fail

134 mortality in patients undergoing veno-venous extracorporeal membrane oxygenation for respiratory fail

135 s (>/= 18 yr old) supported with veno-venous extracorporeal membrane oxygenation for respiratory fail

136 ons in adult patients undergoing veno-venous extracorporeal membrane oxygenation for respiratory fail

137 Adult patients treated with extracorporeal membrane oxygenation for respiratory fail

138 port cohorts were as follows: 1) veno-venous extracorporeal membrane oxygenation for respiratory fail

139 tely 7% of adults supported with veno-venous extracorporeal membrane oxygenation for respiratory fail

140 ctices in patients supported with venovenous extracorporeal membrane oxygenation for severe acute res

141 All primary cases supported with veno-venous extracorporeal membrane oxygenation from 2007 to 2016 (n

142 e consecutive patients who were treated with extracorporeal membrane oxygenation from January 2010 to

143 e higher severity scores at admission in the extracorporeal membrane oxygenation group.

144 mbrane oxygenation and 10,805 donors without extracorporeal membrane oxygenation had at least one org

145 Brain-dead patients with ongoing extracorporeal membrane oxygenation have more severe med

146 Comparative studies with extracorporeal membrane oxygenation have not been comple

147 xtracorporeal membrane oxygenation, and post-extracorporeal membrane oxygenation hypoglycemia were sh

148 on therapy (1D), and we suggest venoarterial extracorporeal membrane oxygenation if available (2D).

149 The use of extracorporeal membrane oxygenation in adults with respi

150 ive recommendation for or against the use of extracorporeal membrane oxygenation in patients with sev

151 core for predicting mortality at the time of extracorporeal membrane oxygenation initiation for child

152 atient undergoing noninvasive ventilation at extracorporeal membrane oxygenation initiation had to be

153 alue of urinary output within 24 hours after extracorporeal membrane oxygenation initiation on mortal

154 rporeal membrane oxygenation patients before extracorporeal membrane oxygenation initiation were asso

155 Following venovenous extracorporeal membrane oxygenation initiation, 97% resp

156 rwent noninvasive ventilation at the time of extracorporeal membrane oxygenation initiation, were ana

157 h G- (48%) (4 [2-10] vs. 13 [7-23] days from extracorporeal membrane oxygenation initiation; p < 0.00

158 better understanding and management of brain/extracorporeal membrane oxygenation interaction to avoid

159 anticoagulation management as well as brain/extracorporeal membrane oxygenation interaction to reduc

160 Extracorporeal membrane oxygenation is a rescue therapy

161 Extracorporeal membrane oxygenation is a rescue therapy

162 Veno-venous extracorporeal membrane oxygenation is an increasingly u

163 Extracorporeal membrane oxygenation may serve as rescue

164 ements included demographic information, pre-extracorporeal membrane oxygenation mechanical ventilati

165 Extracorporeal membrane oxygenation medical directors an

166 iochemical variables, inotrope requirements, extracorporeal membrane oxygenation mode, duration, and

167 ntiation of CICR in isolated cells from this extracorporeal membrane oxygenation model and in cells i

168 Veno-arterial extracorporeal membrane oxygenation offers the advantage

169 between oxygenation measured 24 hours after extracorporeal membrane oxygenation onset and mortality

170 profiles 1 and 2, the need for preoperative extracorporeal membrane oxygenation or renal replacement

171 independent risk factor for poor outcome in extracorporeal membrane oxygenation patients after cardi

172 ence of intracranial hemorrhage was 16.4% in extracorporeal membrane oxygenation patients and 7.6% in

173 predicting hospital mortality in veno-venous extracorporeal membrane oxygenation patients before extr

174 Extracorporeal membrane oxygenation patients experienced

175 Compared to extracorporeal membrane oxygenation patients managed per

176 for Respiratory Failure protocol, usual care extracorporeal membrane oxygenation patients received mo

177 Most extracorporeal membrane oxygenation patients received ne

178 ediction of hospital outcomes in veno-venous extracorporeal membrane oxygenation patients, they do no

179 of a large international cohort of pediatric extracorporeal membrane oxygenation patients.

180 minants of long-term survival in veno-venous extracorporeal membrane oxygenation patients.

181 dence and time course of thrombocytopenia in extracorporeal membrane oxygenation patients.

182 Pediatric Pulmonary Rescue with Extracorporeal Membrane Oxygenation Prediction is a vali

183 The Pediatric Pulmonary Rescue with Extracorporeal Membrane Oxygenation Prediction score inc

184 cute respiratory distress syndrome (ARDS) on extracorporeal membrane oxygenation receiving mechanical

185 ved in these patients with severe ARDS under extracorporeal membrane oxygenation reinforces the need

186 Extracorporeal membrane oxygenation represents a valuabl

187 vivo postarrest myocardial dysfunction using extracorporeal membrane oxygenation resuscitation follow

188 seek to illustrate the impact of veno-venous extracorporeal membrane oxygenation return blood flow up

189 Veno-venous extracorporeal membrane oxygenation return flow generate

190 s to less than 18 years old, with an initial extracorporeal membrane oxygenation run for respiratory

191 e and the University Hospital Regensburg pre-extracorporeal membrane oxygenation score for predicting

192 analyses retained (odds ratio [95% CI]) pre-extracorporeal membrane oxygenation Sequential Organ Fai

193 Only 17% of patients with pre-extracorporeal membrane oxygenation Sequential Organ Fai

194 al was 42%, but better for patients with pre-extracorporeal membrane oxygenation Sequential Organ Fai

195 Venoarterial-extracorporeal membrane oxygenation should be considered

196 y distress syndrome patients managed without extracorporeal membrane oxygenation support (p < 0.001).

197 for fewer days (P = 0.03), less often needed extracorporeal membrane oxygenation support (P = 0.007),

198 ortality in patients undergoing venoarterial extracorporeal membrane oxygenation support following ca

199 In children, the initiation of extracorporeal membrane oxygenation support is associate

200 ventilation, intra-aortic balloon pump, and extracorporeal membrane oxygenation support, respectivel

201 children with respiratory failure receiving extracorporeal membrane oxygenation support.

202 and intracranial hemorrhage occurring during extracorporeal membrane oxygenation support.

203 y to a minimum of 133 G/L by the last day of extracorporeal membrane oxygenation support.

204 ity, hypoxemia, and dependency on venovenous extracorporeal membrane oxygenation support.

205 th community-acquired pneumonia supported on extracorporeal membrane oxygenation survived.

206 The three different extracorporeal membrane oxygenation systems did not show

207 study was to compare the impact of different extracorporeal membrane oxygenation systems on blood hem

208 ere randomly assigned to the three different extracorporeal membrane oxygenation systems.

209 Three different extracorporeal membrane oxygenation systems: the Cardioh

210 ally ventilator-associated pneumonia) during extracorporeal membrane oxygenation therapy are common a

211 redictor of mortality in patients undergoing extracorporeal membrane oxygenation therapy following ca

212 U management may be potential candidates for extracorporeal membrane oxygenation therapy in case of s

213 Over time, miniaturized veno-venous extracorporeal membrane oxygenation therapy increasingly

214 elet count had dropped from 220.5 G/L before extracorporeal membrane oxygenation therapy to a minimum

215 We recommend early initiation of extracorporeal membrane oxygenation therapy to mitigate

216 During the first 5 days of extracorporeal membrane oxygenation therapy, prothrombin

217 matory parameters within the first 5 days of extracorporeal membrane oxygenation therapy.

218 lood hemostasis in adults during veno-venous extracorporeal membrane oxygenation therapy.

219 rs (63%); 41% respondents provide venovenous extracorporeal membrane oxygenation to adults exclusivel

220 vice critical care fellows, simulation-based extracorporeal membrane oxygenation training is superior

221 We compared traditional water-drill-based extracorporeal membrane oxygenation training with simula

222 e oxygenation training with simulation-based extracorporeal membrane oxygenation training with the hy

223 Extracorporeal membrane oxygenation treatment in adult p

224 Extracorporeal membrane oxygenation treatment or extraco

225 patients who survive the first months after extracorporeal membrane oxygenation treatment, long-term

226 acorporeal membrane oxygenation treatment or extracorporeal membrane oxygenation type did not influen

227 pre-extracorporeal membrane oxygenation and extracorporeal membrane oxygenation variables associated

228 (p = 0.91): 86.5% (70.5-94.1) from donors on extracorporeal membrane oxygenation versus 80.7% (79.8-8

229 Although extracorporeal membrane oxygenation volume has increased

230 From 2010 to 2015, extracorporeal membrane oxygenation was initiated in 64

231 p was inserted, and peripheral veno-arterial extracorporeal membrane oxygenation was initiated with s

232 ) (odds ratio, 0.73 [0.57-0.91]; p = 0.009); extracorporeal membrane oxygenation was not an independe

233 Extracorporeal membrane oxygenation was used as a rescue

234 Venoarterial extracorporeal membrane oxygenation was used for cardiac

235 r research, this was the first case in which extracorporeal membrane oxygenation was used to treat se

236 presence of more than three complications on extracorporeal membrane oxygenation were also associated

237 emofiltration, and hyperbilirubinemia during extracorporeal membrane oxygenation were associated with

238 Donors on extracorporeal membrane oxygenation were significantly y

239 n oxygenation and mortality in veno-arterial extracorporeal membrane oxygenation which may be due to

240 ntra-aortic balloon pump and/or venoarterial extracorporeal membrane oxygenation with neurologic inju

241 Only one of 24 patients (4%) initiated on extracorporeal membrane oxygenation within 240 days afte

242 1.5%) died (13.0 deaths/1,000 person-days of extracorporeal membrane oxygenation).

243 fected (50.4 infections/1,000 person-days of extracorporeal membrane oxygenation).

244 ed sixty-five patients underwent veno-venous extracorporeal membrane oxygenation, 775 patients underw

245 nation, 775 patients underwent veno-arterial extracorporeal membrane oxygenation, and 412 underwent e

246 istent pulmonary hypertension, nitric oxide, extracorporeal membrane oxygenation, and American Colleg

247 tion cardiac arrest, the use of inotropes on extracorporeal membrane oxygenation, and post-extracorpo

248 een intra-aortic balloon pump, veno-arterial extracorporeal membrane oxygenation, and significant neu

249 emHeart (CardiacAssist, Pittsburgh, PA), and extracorporeal membrane oxygenation, are more accessible

250 adverse outcome were diagnosis, age at start extracorporeal membrane oxygenation, convulsions, and us

251 shorter ventilation time and lesser need of extracorporeal membrane oxygenation, favored conventiona

252 During veno-venous extracorporeal membrane oxygenation, hypoxemia (odds rat

253 We suggest venoarterial extracorporeal membrane oxygenation, if available, when

254 percutaneous mechanical circulatory support, extracorporeal membrane oxygenation, Impella, and Tandem

255 piratory distress syndrome were supported on extracorporeal membrane oxygenation, including 29 manage

256 duration of mechanical ventilation prior to extracorporeal membrane oxygenation, lower arterial pres

257 Type and duration of extracorporeal membrane oxygenation, neurologic complica

258 xygen of at least 0.30 for at least 4 hours, extracorporeal membrane oxygenation, or mechanical venti

259 In patients requiring extracorporeal membrane oxygenation, short- and long-ter

260 For patients supported with veno-venous extracorporeal membrane oxygenation, the occurrence of i

261 In patients who received veno-venous extracorporeal membrane oxygenation, there was no signif

262 n of unstable VTs can be safely supported by extracorporeal membrane oxygenation, which allows rhythm

263 system, the TandemHeart, and venous-arterial extracorporeal membrane oxygenation-and highlight gaps i

264 Extracorporeal membrane oxygenation-supported ablation w

265 t on outcome of nosocomial infections during extracorporeal membrane oxygenation.

266 derwent urgent surgery, including two during extracorporeal membrane oxygenation.

267 versus 80.7% (79.8-81.6) from donors without extracorporeal membrane oxygenation.

268 ualized at each PEEP level in 15 patients on extracorporeal membrane oxygenation.

269 respiratory failure supported by venovenous extracorporeal membrane oxygenation.

270 lar blockade, prone position ventilation, or extracorporeal membrane oxygenation.

271 crease until day 4-5 after the initiation of extracorporeal membrane oxygenation.

272 d with an increased mortality in veno-venous extracorporeal membrane oxygenation.

273 severe medical conditions than those without extracorporeal membrane oxygenation.

274 enal, and liver insults) than donors without extracorporeal membrane oxygenation.

275 tients diagnosed in France, of whom 161 with extracorporeal membrane oxygenation.

276 ere successfully transplanted from donors on extracorporeal membrane oxygenation.

277 oxygenation and mortality for veno-arterial extracorporeal membrane oxygenation.

278 death (18 vs. 8 deaths/1,000 person-days of extracorporeal membrane oxygenation; p = 0.037) and long

279 xygenation Prediction score included mode of extracorporeal membrane oxygenation; preextracorporeal m

280 had documented thromboembolic event while on extracorporeal membrane oxygenator (prevalence of hepari

281 ed thrombocytopenia-related thrombosis among extracorporeal membrane oxygenator patients at our insti

282 surveillance in a defined high-risk group of extracorporeal membrane oxygenator patients may be neede

283 Ninety-six extracorporeal membrane oxygenator patients met the incl

284 cal data were collected prospectively on all extracorporeal membrane oxygenator patients.

285 eal membrane oxygenator; spent more hours on extracorporeal membrane oxygenator; had significantly hi

286 nts were younger; all underwent venoarterial extracorporeal membrane oxygenator; spent more hours on

287 The extracorporeal optical phase fluorimeter was miniaturise

288 Extracorporeal photopheresis (ECP) is considered a valid

289 increase in regulatory T (Treg) cells after extracorporeal photopheresis (ECP) is thought to contrib

290 Extracorporeal photopheresis is confirmed as an effectiv

291 ft-versus-host disease patients treated with extracorporeal photopheresis, a form of systemic PUVA.

292 pies including prednisone, interleukin-2, or extracorporeal photophoresis.

293 o patients were identified: 250 managed with extracorporeal support and 92 managed using conventional

294 a difference in the need for postprocedural extracorporeal support in favor of the DS group (odds ra

295 secondary outcomes of survival and need for extracorporeal support were analyzed with multivariable

296 nd admission fibrinogen, but not exposure to extracorporeal support, are independently associated wit

297 Until now, efforts to extend gestation using extracorporeal systems have achieved limited success.

298 Individual omics-wide molecular diagnostics, extracorporeal therapies, and drug developments allow fo

299 schlosseri, which has a large, transparent, extracorporeal vascular network encompassing an area >10

300 ng general variables, cross-clamping without extracorporeal veno-venous bypass was the only independe